Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
1QG2 is a Phase 1 study aiming to assess the safety and tolerability of ascending
single/multiple oral doses (SAD & MAD) in healthy young subjects, the preliminary food
interaction and the effect of QGC001 on blood pressure and heart rate, but also to determine
pharmacokinetic preliminary profiles of QGC001 and its metabolite EC33 and pharmacodynamic
preliminary profiles of QGC001 and its metabolite EC33 especially effects on the
renin-angiotensin-aldosterone and copeptin systems.